Loading company…
Odimma Therapeutics develops personalized cancer immunotherapy.
Odimma Therapeutics has developed an immunotherapy drug designed to stimulate an immune response against tumors. It is working on its personalized cancer treatment ODI-2001. Founded in 2017, the company is based in Strasbourg, France. It raised EUR 2 million in seed funding in April 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in